UNSPSC 51313002: Talastine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49AB2PA48B. European Medicines Agency schedules Talastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10801MIG. Talastine generally arises in the molecular formula C19H21N3O.

UNSPSC 51313002 Talastine, a Commodity code, covers pharmaceutical products and naloxone-based harm reduction systems that state and local health agencies procure for community health and emergency response programs. State and local governments buy naloxone delivery systems, drug deactivation equipment, and related pharmaceutical supplies through this code to support opioid crisis response, public health initiatives, and substance abuse treatment infrastructure. The issuing bodies include county health departments, state pharmacy benefit programs, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and state facilities.

Recent activity spans Florida, Texas, and Minnesota with three representative solicitations. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the bid deadline was July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and carry insurance including $5,000,000 commercial general liability per occurrence.